SUMMARY
after enalapril treatment for 9 months, and left ventricular ejection fraction increased in patients with a raised H/M ratio after treatment. Their study differed from ours in that dilated cardiomyopathy was the most common cause of heart failure (about 45%) in their patient group. Also, since the dose of enalapril in our study (2.5-5.0mg/day) was different from those used in these two reports (5-20 and 5-10mg/day, respectively), our results suggest that a low dose of enalapril also improves cardiac sympathetic nerve function. Although Takeishi et al.21) demonstrated that the washout rate as well as the H/M ratio improved significantly after treatment, our results showed that both the early and delayed H/M ratios improved significantly, while the washout rate improved only slightly after enalapril treatment. This difference may reflect the inclusion of 7 patients with old myocardial infarction out of the 10 subjects in our study. This might be caused by an improvement in the sympathetic nerve function in the non-infarcted areas, and an improvement in uptake-1 might have a large influence on this finding due to the increased early H/M ratio. Although it has been shown that myocardial sympathetic reinnervation in denervated, infarcted, and transplanted hearts can be detected by MIBG imaging, [22] [23] [24] , reinnervation in the infarcted area is unlikely to occur for several months in the chronic stage of disease. Even though an improvement in cardiac dilatation might have led to the increased H/M ratios observed in the early and delayed phases, neither the cardio-thoracic ratio nor left ventricular end-diastolic volume determined by radionuclide angiography changed significantly after treatment in the present study, indicating that cardiac dilatation did not improve.
Based on the above findings, the improvement in sympathetic nerve function with ACE inhibitor therapy may result from the improved efficiency of uptake-1, as indicated by an improved early H/M ratio, or by a decrease in MIBG release at the sympathetic nerve endings, represented by the slight improvement in the washout rate. Whether ACE inhibition improves the efficiency of uptake-1 or decreases MIBG release is unknown, and this most likely varies according to the cause of the heart failure. Furthermore, the improvement in hemodynamics due to vasodilation induced by an ACE inhibitor may indirectly result in improved sympathetic nerve function, but the present data do not support this since blood pressure did not change significantly after treatment in our study. The absence of a change in blood pressure in the present study may reflect the use of low doses (2.5-5.0mg/day) of enalapril.
With respect to the relationship between cardiac function and 123I-MIBG myocardial imaging, the improvement rate of the left ventricular ejection fraction was significantly correlated with the improvement of the H/M ratio and the washout rate after treatment with enalapril. These results suggest that 123I-MIBG myocardial imaging may be useful for monitoring the effects of ACE inhibitor Jpn Heart J November 1998 therapy on heart failure. However, the correlations between the %changes in submaximal exercise time and the H/M ratio or washout rate were not significant. These results may reflect the fact that some patients failed to accomplish the target heart rate.
In conclusion, 123I-MIBG might be useful for evaluating the therapeutic effects of enalapril on the cardiac sympathetic nervous system in patients with chronic heart failure.
